Start prescribing Omnipod® 5 with confidence
Prescribing Omnipod 5 may help to improve glycemic control and ease the burden of type 1 diabetes (T1D) care1-3,*
Making the change to Omnipod 5 shouldn’t be a challenge for you or your patients, and the benefits of doing so are clear. See how it could help to improve T1D control for your patients from 2 years of age, with a system that adjusts to their insulin needs and supports them every step of the way.
Flexibility to suit your patients’ needs: that’s our Pod Promise
We all know how important it is to ensure that patients are happy and satisfied with their treatment.
At Insulet, we know that five-year warranty periods on insulin pumps are typically viewed as ‘lock-in’ periods and a potential barrier to patient choice.
To help you and your patients decide, we offer a risk-free Pod Promise guarantee: If your patient starts treatment with our Omnipod 5 or Omnipod DASH® System and decides for any reason that it’s not right for them, they may be eligible for a full refund within the first 90 days following initial training.
For more information, please visit 90 Day Pod Promise Guarantee.
Everything you need to know about prescribing Omnipod 5
Supporting you and your patients every step of the way
Omnipod Clinical Specialists are on hand to introduce people with T1D to Pod Therapy, and to answer any questions that they, or you, may have.
- Patients can register for a 1-hour virtual Pod Therapy 101 webinar to learn more.
Register for Pod 101
We also offer a variety of resources for education and support:
- How-to videos, resources and more
- Your patients can experience the comfort and convenience of the Pod first-hand with the Pod Experience Kit, which includes a needle-free Pod that does not deliver insulin (The Omnipod 5 Controller and/or Omnipod DASH PDM are not included)
What the Omnipod 5 System provides for your patients and practice
Omnipod 5 is an on-body system consisting of a tubeless insulin pump (Pod) with a built-in algorithm that communicates directly with the sensor and Controller to inform automated insulin dosing.2
Omnipod 5 puts simplified T1D management into your patients’ hands. At its heart is SmartAdjust™ technology, proactively managing insulin delivery every 5 minutes using a customized glucose target to help minimize time in hyperglycemia and hypoglycemia.1,2,*,†
Get up-to-date patient data to evaluate their progress with the Glooko® platform, which enables wireless data uploads to support remote and in-person care. Support treatment decisions with actionable insights that combine sensor and insulin data, with rapid identification of trends for personalized care.
Choosing an insulin for Omnipod 5 gives you the choice of a variety of rapid-acting U-100 insulins, so that you can prescribe the one that’s right for your patient.
The following insulins have been tested and found safe for use with Omnipod 5:
- NovoLog®/NovoRapid®
- Humalog®
- Trurapi®/Truvelog®/Insulin aspart Sanofi®,
- Kirsty®
- Admelog®/Insulin lispro Sanofi U-100 insulin
Which patients may benefit from making the switch to Omnipod 5?
Patients who find diabetes management complex
Simplify Life® with Omnipod 5 Automated Insulin Delivery, incorporating a Dexcom G6 or G7 Sensor and SmartAdjust™ technology to make effective T1D care an achievable goal.
Patients struggling to maintain glycemic control
Omnipod 5 delivered significant improvements vs prior therapy (Multiple Daily Injection [MDI] or Continuous Subcutaneous Insulin Infusion [CSII]) in A1c and Time in Range (TIR) for users aged 2 years and older in clinical trials.1,2
Patients who feel burdened by diabetes management
Help your patients realize the freedom and flexibility of on-body, personalized, adaptive T1D control. Using Omnipod 5 has been shown to decrease diabetes distress, potentially helping to ease the substantial burden of T1D management.3
Prescribing Omnipod 5 for children
- Adjusting over time to your young patients’ insulin needs, with SmartAdjust™ technology to help protect them against highs and lows,†
- Tubeless, waterproof‡, on-body, Automated Insulin Delivery (AID), so children can continue their AID when swimming or bathing
- Improved glycaemic outcomes that go hand-in-hand with improved quality of life and mental well-being reported by parents of children with T1D1-4
Prescribing Omnipod 5 for adults
- Adjusting over time to your patients’ needs, with SmartAdjust™ technology to help to protect them against highs and lows,†
- Tubeless, waterproof‡, on-body, Automated Insulin Delivery (AID), so that adults can live their lives without interrupting their AID
- Improved glycemic outcomes that go hand-in-hand with improved patient-reported outcomes such as diabetes distress and stress when eating1,2
† Results from two pivotal single-arm, multicentre, prospective studies in participants with T1D aged 6–70 years (112 children aged 6–13.9 years and 129 adolescents/adults aged 14–70 years) and 80 very young children with T1D (2.0–5.9 years).1,2
‡ The Pod has a waterproof IP28 rating for up to 25 feet for 60 minutes. The controller is not waterproof. The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under 2.4 m (8 feet) of water for up to 24 hours without failure when properly installed.
How to get started
To help you and your patients start Omnipod 5 with ease, we offer a variety of live and online educational and support resources.
The Omnipod 5 Automated Insulin Delivery System is now available in Canada; however, provincial coverage across Canada may take some time.
Starting a patient on Omnipod DASH now allows them to become familiar with the Pod and PDM, making transitioning to Omnipod 5 in the future easier.
Our Omnipod Innovation Pathway will provide your patients with access to the newest Omnipod technology.§ This program allows in-warranty patients the freedom to switch to new Omnipod technology once it becomes available in Canada.¶
For more information, please visit the Omnipod Innovation Pathway.
Be the first to know
Stay up to date and be in the know when it comes to all things Insulet. By signing up for our mailing list, you will be in the know when it comes to training and events, provincial coverage updates, Omnipod published data and first-hand experiences from Podders.
†If glucose alerts and readings from the sensor do not match symptoms or expectations, a blood glucose meter should be used to make diabetes treatment decisions.
‡The Pod has an IP28 rating for up to 7.6 metres (25 feet) for up to 60 minutes. The Controller is not waterproof. Please consult sensor manufacturer user guide for sensor waterproof rating.
§Terms and conditions apply. Eligibility may vary. Click on Omnipod Innovation Pathway for full terms.
¶When covered by public and private payors.
References:
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in adults/adolescents and children as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, p<0.0001 and ST = 52.5%, 3-mo Omnipod 5 = 68.0%, p<0.0001. Mean HbA1c: ST vs. Omnipod 5 use in adults/adolescents (14-70 yrs) and children (6-13.9 yrs), respectively (7.16% vs 6.78% or 55 mmol/mol vs. 51 mmol/mol, p<0.0001; 7.67% vs 6.99% or 60mmol/mol vs 53 mmol/mol), p<0.0001). Mean time in hypoglycaemic range in adults/adolescents and children (<3.9 mmol/L or <70mg/dL as measured by CGM) as measured by CGM: ST = 1.89%, 3-mo Omnipod 5 = 1.32%, p<0.0001 and 2.21%, 3-mo Omnipod 5 = 1.78%, p<0.0456.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5system. Mean HbA1c as measured in very young children, ST vs. Omnipod 5 use:7.4% vs 6.9% or 57 mmol/ml vs. 53 mmol/mol; (p<0.0001). Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, p<0.0001. Mean time in hypoglycaemic range (<3.9mmol/L or <70 mg/dL as measured by CGM) ST = 3.43% vs Omnipod 5: 2.46%, p<0.0001.
3. Polonsky WH et al. Diabetes Res Clin Pract 2022;190:109998. During the Omnipod 5 pivotal trial, adults aged 18-70 (N=115) experienced an improved diabetes distress survey score after 3 months of AID use: mean: 1.48 vs. 1.64 (p< 0.001).
4. Hood KK, et al. Pediatric Diabetes 2023. During the Omnipod 5 pivotal trial, parents of children aged 6-11.9 years (N=82) experienced an improvement in emotional distress levels and mental well-being survey scores after 3 months of Omnipod 5 use compared to standard therapy: mean P-PAID-C score = 40.7 vs. 47.4; mean WHO-5 score = 72.9 vs. 67.5, respectively.